| Theme | Gastroenteropancreatic Neuroendocrine Tumors | |
|---|---|---|
| Title | Chemotherapy for Neuroendocrine Neoplasms : Cytotoxic and Molecular-Targeted Therapies | |
| Publish Date | 2013/01 | |
| Author | Hideyuki Hayashi | Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital |
| Author | Chigusa Morizane | Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital |
| Author | Yasunari Sakamoto | Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital |
| Author | Shunsuke Kondo | Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital |
| Author | HHideki Ueno | Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital |
| Author | Takuji Okusaka | Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital |
| [ Summary ] | Neuroendocrine neoplasms are rare diseases with limited treatment options available to date, making their treatment extremely difficult. Neuroendocrine neoplasms can be classified into two categories：neuroendocrine tumors (NET) G1/G2, or neuroendocrine carcinoma (NEC). For treatment of NEC, combination chemotherapy regimens consisting of cisplatin and etoposide, or cisplatin and irinotecan (which is a conventional treatment for small cell lung carcinoma) have been widely applied. For treatment of NET G1/G2, large prospective, randomized controlled trials have confirmed the efficacy of new drugs, such as sunitinib and everolimus. Interest in the treatment of NET G1/G2 using these new drugs is increasing. | |